Combo Products Would Usually Require Payment Of Only One User Fee, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance on user fees states that the amount paid would be equivalent to one PDUFA fee when FDA requires two applications for an “innovative combination product.” FDA is developing guidance on when single or multiple applications should be submitted.
You may also be interested in...
Separate Marketing Applications Will Be Assessed Their Own User Fees – FDA
Agency guidance discusses when to submit a separate application as opposed to a supplement. The Medicare Rx law may require a separate application to be submitted if there is a change to the reference listed drug, the guidance states.
Separate Marketing Applications Will Be Assessed Their Own User Fees – FDA
Agency guidance discusses when to submit a separate application as opposed to a supplement. The Medicare Rx law may require a separate application to be submitted if there is a change to the reference listed drug, the guidance states.
Industry Seeks Clarification On Applicability Of Regs For Combo Products
Comments on FDA's combination products draft guidance ask for clarification of the regulatory requirements when the separate components are produced as a single entity or co-packaged. FDA views the dual applicability as manageable since there is "considerable overlap" between pharmaceutical cGMPs and device quality system regs.